Related references
Note: Only part of the references are listed.Severe anemia early in life as a risk factor for sickle-cell kidney disease
Inmaculada Aban et al.
BLOOD (2017)
Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology
Dachuan Zhang et al.
BLOOD (2016)
Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use
Nancy S. Green et al.
PEDIATRIC BLOOD & CANCER (2016)
CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil
Helena Almqvist et al.
NATURE COMMUNICATIONS (2016)
The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent
Carmen Brenner et al.
ONCOTARGET (2016)
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes
Yogen Saunthararajah et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer
Melania Zauri et al.
NATURE (2015)
Subchronic Oral Toxicity Study of Decitabine in Combination With Tetrahydrouridine in CD-1 Mice
Pramod Terse et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2014)
The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells
M. F. Whelihan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Epigenetic action of decitabine (5-aza-2′-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C)
Richard L. Momparler et al.
LEUKEMIA RESEARCH (2013)
Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A
Jian Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Mortality Rates and Age at Death from Sickle Cell Disease: US, 1979-2005
Sophie Lanzkron et al.
PUBLIC HEALTH REPORTS (2013)
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine
Donald Lavelle et al.
BLOOD (2012)
Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation
Matthew F. Whelihan et al.
BLOOD (2012)
Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin
Duyen A. Ngo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
Hsing-Chen Tsai et al.
CANCER CELL (2012)
Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study
Robert S. Jansen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
Oscar Alcazar et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
S. Negrotto et al.
LEUKEMIA (2012)
DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes
Eriko G. Clements et al.
NUCLEIC ACIDS RESEARCH (2012)
p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies
Yogen Saunthararajah et al.
SEMINARS IN ONCOLOGY (2012)
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
Quteba Ebrahem et al.
ONCOTARGET (2012)
Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia
Jeffrey Lebensburger et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
A pilot study of subcutaneous decitabine in β-thalassemia intermedia
Nancy F. Olivieri et al.
BLOOD (2011)
Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease
Santosh Saraf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Soledad Negrotto et al.
CANCER RESEARCH (2011)
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Nuclear Receptors TR2 and TR4 Recruit Multiple Epigenetic Transcriptional Corepressors That Associate Specifically with the Embryonic β-Type Globin Promoters in Differentiated Adult Erythroid Cells
Shuaiying Cui et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia
K. P. Ng et al.
LEUKEMIA (2011)
A Phase 1 and Pharmacodynamic Study of Decitabine in Combination With Carboplatin in Patients With Recurrent, Platinum-Resistant, Epithelial Ovarian Cancer
Fang Fang et al.
CANCER (2010)
Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage
Chiara Conti et al.
CANCER RESEARCH (2010)
Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus
Zhenbo Hu et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme
Katan Patel et al.
NUCLEIC ACIDS RESEARCH (2010)
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
J-H. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
David J. Stewart et al.
CLINICAL CANCER RESEARCH (2009)
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors
Ana Aparicio et al.
EPIGENETICS (2009)
Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma
Armando Tripodi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Platelet count and the risk for thrombosis and death in the elderly
J. G. van der Bom et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Platelet count in essential thrombocythemia: the more the better?
Ayalew Tefferi
BLOOD (2008)
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells
Anna Scuto et al.
BLOOD (2008)
Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and Bioavailability in mice by 3,4,5,6-tetrahydrouridine
Jan H. Beumer et al.
CLINICAL CANCER RESEARCH (2008)
Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia
Aida Habib et al.
HAEMATOLOGICA (2008)
Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!
Mark T. Gladwin et al.
HAEMATOLOGICA (2007)
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension
Kenneth Ataga et al.
HAEMATOLOGICA (2007)
Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation
Lothar Schermelleh et al.
NUCLEIC ACIDS RESEARCH (2007)
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
Zhongfa Liu et al.
NUCLEIC ACIDS RESEARCH (2007)
Fine Tuning of Globin Gene Expression by DNA Methylation
Alon Goren et al.
PLOS ONE (2006)
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura
David S. Schrump et al.
CLINICAL CANCER RESEARCH (2006)
Hydroxyurea and sickle cell anemia: effect on quality of life
Samir K. Ballas et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?
Terry J. Gaymes et al.
MOLECULAR CANCER RESEARCH (2006)
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease
Roberto F. Machado et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2 '-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method
ZF Liu et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
DNA hypo-methylating agents and sickle cell disease
Y Saunthararajah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A
M Milhem et al.
BLOOD (2004)
Effect of hydroxyurea on mortality. and morbidity in adult sickle cell anemia - Risks and benefits up to 9 years of treatment
MH Steinberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Effects of 5-aza-2 '-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease
Y Saunthararajah et al.
BLOOD (2003)
Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia
J DeSimone et al.
BLOOD (2002)
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy
RE Ware et al.
BLOOD (2002)
Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion
BNY Setty et al.
BLOOD (2001)
Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease
GF Atweh et al.
CURRENT OPINION IN HEMATOLOGY (2001)
Share Paper
